November 12, 2024 Asieris Unveils Results for the First Time at 2024 IPVC the Analysis of the of HPV Clearance Rate for Different HPV Types and Different Follow-up Times of the Non-Surgical Treatment for Cervical HSIL Product APL-1702 Clinical Study
November 7, 2024 Asieris Pharmaceuticals and China Women’s Development Foundation Sign Strategic Cooperation Agreement for ‘Fertility-Friendly Cervical Health Initiative’
November 6, 2024 Cancer Foundation of China and Asieris Pharmaceuticals Forge Strategic Partnership for Cervical Cancer Prevention and Control
November 5, 2024 Asieris Showcases World’s 1st Product for Non-Invasive Treatment of Precancerous Cervical Lesions at its CIIE Debut
October 24, 2024 Asieris Received FDA IND Approval for a Novel USP1 Inhibitor for the Treatment of Advanced Solid Tumors
October 22, 2024 Asieris Pharmaceuticals and ECUST’s School of Chemistry and Molecular Engineering Forge Strategic Partnership on Photodynamic Platforms
October 21, 2024 Asieris Pharmaceuticals Appoints Richard Zhao as Senior Vice President of Business Development
September 29, 2024 Asieris Unveils Results for the First Time at 2024 CSCO Conference the Subgroup Analysis of Pathological Regression Rate and HPV Clearance Rate at 6 Months in Different Age Groups of the Non-Surgical Treatment for Cervical HSIL Product APL-1702 Clinical Study
September 25, 2024 Encouraging Efficacy Signals Achieved in Phase II Clinical Trial of Asieris APL-1202 in Combination with PD-1 Inhibitor Tislelizumab for Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer
September 17, 2024 Asieris Unveils Results for the First Time at 2024 PDT&PD Conference the Efficacy Data of Non-Surgical Treatment of Cervical HSIL with APL-1702 in Reducing the Histological Grade of Cervical Precancerous Lesions
August 28, 2024 Asieris Pharmaceuticals Releases 2024 Semi-Annual Report, Highlighting Steady Progress in Launching Blockbuster Product for Precancerous Cervical Lesions and Continued Strengthening of Commercial Revenue Generation Capabilities
June 24, 2024 Asieris’ APL-1202 Investigational New Drug (IND) Approved by NMPA for Treating Free-living Amoebae Infections
June 12, 2024 Asieris Publishes Latest Research Findings on APL-1401 for the Treatment of Active Ulcerative Colitis in Cellular Immunology
May 12, 2024 Asieris announces NMPA acceptance of NDA for APL-1702, a non-surgical therapy for treating cervical HSIL
April 17, 2024 Asieris Pharmaceuticals Unveils 2023 Annual Report, Core Product APL-1702 Succeeds in Global Phase III Clinical Trials, APL-1706 obtains NDA acceptance domestically, Specialty Commercial Team Generates Sustained Revenue Streams
April 8, 2024 Asieris Pharmaceuticals Releases the Drug and Equipment Performance Results from the Phase III Clinical Study of the Bladder Cancer Diagnostic and Management Drug APL-1706 in Combination with HD 4K Blue Light Cystoscopy
April 1, 2024 Asieris Pharmaceuticals to Present the Drug and Equipment Performance Results from the Phase III Clinical Study of the Bladder Cancer Diagnostic and Management Drug APL-1706 in Combination with HD 4K Blue Light Cystoscopy
March 18, 2024 Breakthrough in Treatment of Cervical High-Grade Squamous Intraepithelial Lesion: Release of Positive Results from Multicenter Phase III Global Clinical Study
March 11, 2024 Asieris’ Two Research Achievements to be Presented at the 2024 American Association for Cancer Research Annual Meeting, Exploring More Treatment Possibilities
March 4, 2024 Asieris to Unveil Results of the international multicenter Phase III clinical Study for APL-1702, a non-surgical treatment for cervical HSIL, at the 2024 SGO Annual meeting
March 3, 2024 Asieris to Unveil First-ever Results of the international multicenter Phase III clinical Study for APL-1702, a non-surgical treatment for cervical HSIL, at the 2024 EUROGIN CONGRESS
February 22, 2024 Asieris to Unveil Results of the international multicenter Phase III clinical Study for 1702, a non-surgical treatment for cervical HSIL, at the 2024 SGO Annual Meeting
February 21, 2024 Asieris to Unveil First-ever Results of the international multicenter Phase III clinical Study for 1702, a non-surgical treatment for cervical HSIL, at the 2024 EUROGIN
January 28, 2024 Asieris Reveals Phase III Clinical Study and Real-World Data for APL-1706, a Novel Bladder Cancer Diagnosis and Management Drug, at 2024 ASCO-GU
January 28, 2024 Asieris Announces Promising Interim Results for APL-1202 in Combination with Tislelizumab for Muscle-Invasive Bladder Cancer Treatment at 2024 ASCO-GU
January 23, 2024 Asieris will Present for the First Time Interim Analysis Data of Oral APL-1202 in Combination with PD-1 Inhibitor Tislelizumab for Neoadjuvant Treatment of Muscle-Invasive Bladder Cancer at 2024 ASCO-GU
January 8, 2024 Asieris’ Breast Cancer Product Ouyoubi Makes Inaugural Landings in Twenty Cities, Steadily Advancing Domestic Commercialization Process
January 8, 2024 Enhancing Leadership in Gynecology, Asieris Pharmaceuticals Appoints Sophia Cao to Lead the Newly-Established Women’s Health Business Unit, Accelerating Strategic Expansion
October 6, 2023 Asieris to Unveil First-ever Results of the Phase III Clinical Study for APL-1706, an Imaging Drug for Diagnosis or Surgery of Bladder Cancer, at the 2023 SIU Annual Meeting September 20, 2023 The First Non-Vaccine Investigational Product for Cervical HSIL has Achieved Its Primary Endpoint September 14, 2023 Asieris’ New Drug APL-1401 Completes First Administration in Patient with Moderately to Severely Active UC September 13, 2023 Asieris Announces Positive Interim Analysis Results in Phase II Clinical Trial of Oral APL-1202 in Combination with Tislelizumab, a PD-1 inhibitor, as Neoadjuvant Therapy for Muscle Invasive Bladder Cancer August 29, 2023 Asieris Obtained IND Approval from NMPA for APL-1401, a Drug for the Treatment of Moderately-to-Severely Active Ulcerative Colitis August 22, 2023 Asieris Pharmaceuticals Unveils 2023 Semi-Annual Report, Demonstrating Initial Success of Specialty Pharma Strategy and Multi-Product Synergistic Commercialization August 22, 2023 Highlights of Asieris Pharmaceuticals 2023 Semi-Annual Report August 15, 2023 Hong Kong Department of Health has Approved the Registration Applications for the Uro-G and Uro-V Disposable Cystoscopic System August 11, 2023 Asieris Announces Positive Result from Phase III Bridging Trial of Hexvix®, a Diagnostic Drug for Bladder Cancer July 6, 2023 Asieris has completed the China Phase III Bridging Trial Enrollment of Hexvix®, a Diagnostic Drug for Bladder Cancer May 31, 2023 Asieris’ progress in MIBC receives renewed attention with its inclusion in ASCO 2023 May 18, 2023 Asieris Deepens Strategic Partnership with UroViu to Further Develop Integrated Diagnosis and Treatment Platform for Bladder Cancer April 17, 2023 Asieris Releases 2022 Annual Report: Make Steady Progress in its Clinical Development, Global Expansion to Treat Genitourinary Tumors, and Implementing its Commercialization Strategy to Provide Integrated Diagnosis-to-Treatment Solutions April 17, 2023 Highlights of Asieris Pharmaceuticals 2022 Annual Report April 10, 2023 Asieris’ subsidiary makes significant progress in its commercialization strategy by obtaining the “Drug Distribution License” February 20, 2023 NMPA accepted the registration applications for Uro-G and Uro-3500 February 9, 2023 Asieris Drug Plays Pivotal Role to Help UCSF Save a Life February 7, 2023 Asieris and ReviR Enter into Research Collaboration Agreement to Discover Oncology Therapeutics Based on ReviR’s Comprehensive Approach to RNA-targeting Technologies January 17, 2023 Asieris Appoints Dr. Linda Wu as Chief Development Officer
October 6, 2023 Asieris to Unveil First-ever Results of the Phase III Clinical Study for APL-1706, an Imaging Drug for Diagnosis or Surgery of Bladder Cancer, at the 2023 SIU Annual Meeting
September 20, 2023 The First Non-Vaccine Investigational Product for Cervical HSIL has Achieved Its Primary Endpoint
September 14, 2023 Asieris’ New Drug APL-1401 Completes First Administration in Patient with Moderately to Severely Active UC
September 13, 2023 Asieris Announces Positive Interim Analysis Results in Phase II Clinical Trial of Oral APL-1202 in Combination with Tislelizumab, a PD-1 inhibitor, as Neoadjuvant Therapy for Muscle Invasive Bladder Cancer
August 29, 2023 Asieris Obtained IND Approval from NMPA for APL-1401, a Drug for the Treatment of Moderately-to-Severely Active Ulcerative Colitis
August 22, 2023 Asieris Pharmaceuticals Unveils 2023 Semi-Annual Report, Demonstrating Initial Success of Specialty Pharma Strategy and Multi-Product Synergistic Commercialization
August 15, 2023 Hong Kong Department of Health has Approved the Registration Applications for the Uro-G and Uro-V Disposable Cystoscopic System
August 11, 2023 Asieris Announces Positive Result from Phase III Bridging Trial of Hexvix®, a Diagnostic Drug for Bladder Cancer
July 6, 2023 Asieris has completed the China Phase III Bridging Trial Enrollment of Hexvix®, a Diagnostic Drug for Bladder Cancer
May 18, 2023 Asieris Deepens Strategic Partnership with UroViu to Further Develop Integrated Diagnosis and Treatment Platform for Bladder Cancer
April 17, 2023 Asieris Releases 2022 Annual Report: Make Steady Progress in its Clinical Development, Global Expansion to Treat Genitourinary Tumors, and Implementing its Commercialization Strategy to Provide Integrated Diagnosis-to-Treatment Solutions
April 10, 2023 Asieris’ subsidiary makes significant progress in its commercialization strategy by obtaining the “Drug Distribution License”
February 7, 2023 Asieris and ReviR Enter into Research Collaboration Agreement to Discover Oncology Therapeutics Based on ReviR’s Comprehensive Approach to RNA-targeting Technologies
December 18, 2023 Asieris Successfully Convenes First Domestic Breast Cancer Care Forum and National Product Launch Conference for Ouyoubi in Shanghai
December 14, 2023 Two Asieris Studies in the Field of Bladder Cancer Selected for Oral and Poster Presentations at the 2024 American Society of Clinical Oncology Genitourinary Cancer Symposium, Potentially Offering New Disease Management Options for Patients
November 29, 2023 Asieris announces NMPA has accepted the New Drug Application for APL-1706, an Imaging Drug for Diagnosing and Management of Bladder Cancer
October 16, 2023 Asieris’First Product Dipaite Achieves Commercialization and Launches in China, First Prescription Issued in Shanghai
October 12, 2023 Asieris Unveiled Results of Its Phase III Clinical Study for APL-1706, an Imaging Drug for Diagnosis or Surgery of Bladder Cancer, at the SIU 2023 Congress
December 12, 2022 Asieris’ Bladder Cancer Diagnostic Drug Hexvix® Completed Dosing of First Patient in Real-World Clinical Study
November 14, 2022 Asieris named “2022 TOP 20 Most Influential Innovative Enterprises in Small Molecule Drugs”
November 11, 2022 The Oral APL-1202 in Combination with PD-1 inhibitor Tislelizumab as Neoadjuvant Therapy has Entered Phase II Clinical Study
November 10, 2022 Asieris Obtained IND Approval from US FDA for APL-1401, a New Drug for the Treatment of Moderately-to-Severely Active Ulcerative Colitis
November 4, 2022 Hexvix®, A Diagnostic Drug for Bladder Cancer of Asieris, Completed the First Patient Dose in Phase III Trial
September 15, 2022 Hexvix®, A Diagnostic Drug of Asieris, is Now Covered by the 2022 Lecheng Global Specialty Drug Insurance
August 25, 2022 Asieris Pharmaceuticals (688176.SH) Issued 2022 Semi-Annual Report: Accelerated Global Clinical Development and Progressive Implementation of Its Integrated Diagnosis-Treatment Commercialization Strategy
August 22, 2022 Asieris on Science and Technology Innovation Board “2022 Most Innovative Companies” List
August 9, 2022 Asieris’ Multinational Phase III Clinical Trial for the Non-Surgical Treatment of HSIL Has Completed Enrollment
August 8, 2022 The First Domestic Case in Boao, Ushering in a New Option for Diagnosing Bladder Cancer
June 9, 2022 Asieris to publish the study protocol of Cevira® as a novel treatment in patients with high grade squamous intraepithelial lesion (HSIL) on BMJ Open
May 27, 2022 Asieris to present a study protocol of APL-1202 in combination with BeiGene’s tislelizumab as neoadjuvant therapy (NAC) for muscle invasive bladder cancer (MIBC) patients at 2022 ASCO annual meeting
April 15, 2022 Asieris Pharmaceuticals Announces 2021 Annual Report: Steady Progress in Core Product Pipeline and Progressive Implementation of the Integrated Diagnosis and Treatment Commercialization Strategy
March 26, 2022 Now Hiring: Head of Toxicology, Director to Senior Director (Shanghai or San Francisco)
January 4, 2022 World’s First Patient Dose Administered in Combination of Asieris’ APL-1202 and BeiGene’s Tislelizumab as Neoadjuvant Therapy for MIBC Patients
October 13, 2021 The CDE Approved IND Application to Investigate Combination of Asieris’ APL-1202 and BeiGene’s Tislelizumab as Neoadjuvant Therapy for MIBC Patients
September 26, 2021 Asieris Named One of Top 30 Chinese Innovative Enterprises in Small Molecule Drugs
September 22, 2021 Asieris Appoints Dr. Alice Chen as Senior Vice President, Discovery Biology and Head of Translational Research
June 22, 2021 Asieris Announces First Patient Treated in Europe in APRICITY, the Multinational Phase III Clinical Trial of APL-1702, Cevira®
June 14, 2021 The U.S. FDA Approved IND Application to Investigate Combination of Asieris’ APL-1202 and BeiGene’s Tislelizumab as Neoadjuvant Therapy for MIBC Patients
May 20, 2021 Asieris and Sinopharm Enter into Strategic Partnership to Accelerate Commercialization of Asieris Products
May 6, 2021 Asieris and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of APL-1202 and Tislelizumab
April 8, 2021 Asieris Appoints Dr. Tie-Lin Wang as Senior Vice President, Head of Discovery Chemistry and Pre-Clinical Development
January 26, 2021 Asieris and Photocure Expand Strategic Partnership to Bladder Cancer Diagnosis and Surgery in Mainland China and Taiwan
January 25, 2021 Asieris Appointed Dr. Yong Xue as Chief Medical Officer and Mr. Xinming Jiang as VP of Sales and Marketing
November 12, 2020 Asieris Announces First Patient Enrollment in the Global Phase III Clinical Trial for APL-1702
October 30, 2020 Asieris Announces Approval of its Phase III Trial of a Novel Single Oral Agent as First-line Treatment for Non-Muscle Invasive Bladder Cancer (NMIBC)
July 8, 2020 Asieris Received China NMPA’s Approval to Start a Global Phase III Clinical Trial for APL-1702 to Treat Cervical Precancerous Lesions (HSIL)
July 1, 2020 Asieris Appointed Dr. Susan Wang as Senior Vice President of Global Business Development
June 28, 2020 Asieris Announced the Completion of Series C+ Round Financing – to Accelerate the Commercialization
March 24, 2020 Asieris Announced the Completion of Series C Round Financing- to Accelerate the Global Development of Its Innovative Drugs
March 1, 2019 Asieris CEO to Host CEO Roundtable at Upcoming WuXi Healthcare Forum 2019 January 1, 2019 Asieris to Participate in the Upcoming 12th European Life Sciences CEO Forum
July 2, 2019 Asieris and Photocure Enter into a License Agreement for World-Wide Development and Commercialization of Cevira®
March 21, 2019 Asieris’s Executives to Participate in the Upcoming Asia Pharma R&D Leaders Summit 2019
